User profiles for S. Attarian
Shahram AttarianCHU La Timone , Aix-Marseille Université Verified email at ap-hm.fr Cited by 12256 |
[HTML][HTML] Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
…, JL Berk, KP Lin, G Vita, S Attarian… - New england journal …, 2018 - Mass Medical Soc
Background Patisiran, an investigational RNA interference therapeutic agent, specifically
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …
inhibits hepatic synthesis of transthyretin. Methods In this phase 3 trial, we randomly assigned …
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy …
…, P Vankrunkelsven, JA Allen, S Attarian… - Journal of the …, 2021 - Wiley Online Library
To revise the 2010 consensus guideline on chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two …
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and two …
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
…, MPG Stemmerik, H Andersen, S Attarian… - The Lancet …, 2021 - thelancet.com
Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients…
that are effective, targeted, well tolerated, and can be used in a broad population of patients…
[HTML][HTML] The neurodevelopmental impact of neonatal morphine administration
S Attarian, LC Tran, A Moore, G Stanton, E Meyer… - Brain Sciences, 2014 - mdpi.com
… Despite this, many physicians remain reluctant to administer morphine as they fear detrimental
neurological effects and are unsure of it’s role after recommendations from Bellu’s 2008 …
neurological effects and are unsure of it’s role after recommendations from Bellu’s 2008 …
Hereditary and inflammatory neuropathies: a review of reported associations, mimics and misdiagnoses
…, D Adams, P Latour, S Attarian - Journal of Neurology …, 2016 - jnnp.bmj.com
… will take you to the Copyright Clearance Center’s RightsLink service. You will be able to
get a … reduction of timed 10 m walk from 20 to 10 s. She subsequently became IVIg-dependent. …
get a … reduction of timed 10 m walk from 20 to 10 s. She subsequently became IVIg-dependent. …
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo …
…, M Saarela, M Auranen, J Pouget, S Attarian… - The Lancet …, 2018 - thelancet.com
Background Approximately two-thirds of patients with chronic inflammatory demyelinating
polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous …
polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous …
Regional variation of Guillain-Barré syndrome
…, DR Cornblath, HJ Willison, Z Islam, S Attarian… - Brain, 2018 - academic.oup.com
Guillain-Barré syndrome is a heterogeneous disorder regarding the clinical presentation,
electrophysiological subtype and outcome. Previous single country reports indicate that Guillain…
electrophysiological subtype and outcome. Previous single country reports indicate that Guillain…
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
…, B Avau, P Vankrunkelsven, S Attarian… - Journal of the …, 2023 - Wiley Online Library
… Shahram Attarian reports speaker honorary and travel support: LFB, Alnylam, Akcea, Pfizer,
Sanofi, Pharnext, Inflectis, Biogen, Novartis Hansa, UCB, Argenx, Alexion and Roche. Board …
Sanofi, Pharnext, Inflectis, Biogen, Novartis Hansa, UCB, Argenx, Alexion and Roche. Board …
Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes
…, D Figarella-Branger, N Romero, S Attarian… - Archives of …, 2007 - jamanetwork.com
… girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). …
girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). …
girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). …
Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial
…, B Eymard, T Stojkovic, S Attarian, S Chevret… - Archives of …, 2005 - jamanetwork.com
Background The optimal dose of intravenous immunoglobulin (IVIG) in acute exacerbation
of myasthenia gravis remains unknown. Increasing the treatment duration might provide …
of myasthenia gravis remains unknown. Increasing the treatment duration might provide …